-
公开(公告)号：US20250011813A1
公开(公告)日：2025-01-09
申请号：US18774670
申请日：2024-07-16
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
公开(公告)号：US20230348936A1
公开(公告)日：2023-11-02
申请号：US18301818
申请日：2023-04-17
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
CPC classification number: C12N15/86 , C12N15/01 , C12N15/63 , C12N2750/14152 , C12N2750/14122 , C12N2750/14143
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
公开(公告)号：US10793839B2
公开(公告)日：2020-10-06
申请号：US16107009
申请日：2018-08-21
Applicant: Cevec Pharmaceuticals GmbH
Inventor： Silke Wissing , Jens Wölfel , Nicole Faust
IPC: C12N9/10 , C12P21/00 , C07K14/475 , C07K14/81
Abstract: The present invention relates to cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.
-
公开(公告)号：US20200377895A1
公开(公告)日：2020-12-03
申请号：US16636622
申请日：2018-08-01
Applicant: CEVEC Pharmaceuticals GmbH
Inventor： Nicole Faust , Silke Wissing , Nikola Strempel
Abstract: The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.
-
公开(公告)号：US20200277628A1
公开(公告)日：2020-09-03
申请号：US16646741
申请日：2018-09-18
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
IPC: C12N15/86
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
Patent Agency Ranking
公开(公告)号：US12060569B2
公开(公告)日：2024-08-13
申请号：US18301818
申请日：2023-04-17
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
CPC classification number: C12N15/86 , C12N15/01 , C12N15/63 , C12N2750/14122 , C12N2750/14143 , C12N2750/14152
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
公开(公告)号：US12060561B2
公开(公告)日：2024-08-13
申请号：US16636622
申请日：2018-08-01
Applicant: CEVEC Pharmaceuticals GmbH
Inventor： Nicole Faust , Silke Wissing , Nikola Strempel
IPC: C07K14/705 , C07K14/71 , C07K19/00 , C12N5/07 , C12N5/071 , C12N5/10 , C12N5/16 , C12N15/09 , C12N15/113 , C12N15/62 , C12N15/63 , C12N15/85
CPC classification number: C12N15/62 , C07K14/70517 , C07K14/71 , C07K19/00 , C12N5/06 , C12N5/0625 , C12N5/10 , C12N5/16 , C12N15/09 , C12N15/1138 , C12N15/63 , C12N15/85 , C07K2319/00 , C12N2501/105
Abstract: The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.
-
公开(公告)号：US20200095562A1
公开(公告)日：2020-03-26
申请号：US16107009
申请日：2018-08-21
Applicant: Cevec Pharmaceuticals GmbH
Inventor： Silke Wissing , Jens Wölfel , Nicole Faust
IPC: C12N9/10 , C12P21/00 , C07K14/475 , C07K14/81
Abstract: The present invention relates to cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.
-
公开(公告)号：US20250002923A1
公开(公告)日：2025-01-02
申请号：US18769083
申请日：2024-07-10
Applicant: CEVEC Pharmaceuticals GmbH
Inventor： Nicole Faust , Silke Wissing , Nikola Strempel
IPC: C12N15/62 , C07K14/705 , C07K14/71 , C07K19/00 , C12N5/07 , C12N5/071 , C12N5/10 , C12N5/16 , C12N15/09 , C12N15/113 , C12N15/63 , C12N15/85
Abstract: The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.
-
公开(公告)号：US11685932B2
公开(公告)日：2023-06-27
申请号：US16646741
申请日：2018-09-18
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
CPC classification number: C12N15/86 , C12N15/01 , C12N15/63 , C12N2750/14122 , C12N2750/14143 , C12N2750/14152
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.011 seconds)
